Format

Send to

Choose Destination
Curr Opin Urol. 2018 Mar;28(2):132-138. doi: 10.1097/MOU.0000000000000477.

Oncologic outcomes after minimally invasive surgery for cT1 renal masses: a comprehensive review.

Author information

1
Department of Urology, Medical University of Vienna, Vienna, Austria.
2
Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania.
3
Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.
4
Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
5
Division of Urology, Virginia Commonwealth University, Richmond, Virginia, USA.
6
Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.
7
Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
8
Department of Urology, Weill Cornell Medical College, New York, New York, USA.

Abstract

PURPOSE OF REVIEW:

To evaluate current literature reporting oncologic outcomes after robot-assisted partial nephrectomy (RAPN) and laparoscopic partial nephrectomy (LPN).

RECENT FINDINGS:

Recently, there have been published first mid-term results after RAPN (5 years). To date, there are no randomized trials to guide decision-making regarding LPN or robotic partial nephrectomy (RPN), and such trials are unlikely to be forthcoming, given the rapid adoption of RAPN worldwide. We performed a literature search according to Cochrane guidelines up to 1 September 2017, including studies that had more than 40 months of oncologic follow-up.

SUMMARY:

A total of 2933 patients were included from 14 studies (1498 RAPN, 1525 LPN). RAPN had similar mid-term (5 years) oncologic outcomes as LPN. Large collaborative efforts are still necessary to provide solid long-term oncologic outcomes of open, laparoscopic, and RPN.

PMID:
29278581
DOI:
10.1097/MOU.0000000000000477
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center